Company: MIRA
Filing Date: 2025-07-29
Form Type: PRER14A
Source: 0001641172-25-021434
Chunk: 115

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-07-29
Form: PRER14A
Chunk 115
---
1) | Unless                                                                                             
 otherwise denoted, the address of each noted person is 1200 Brickell Avenue, Suite 1950 #1183,     
 Miami, Florida 33131.                                                                              |
| (2) | Consists                                                                                           
 of (i) 782,200 shares of common stock and (2) options to purchase 3,479,000 shares of common       
 stock.                                                                                             |
| (3) | Includes                                                                                           
 (i) 10,000 shares held directly by Mr. McNulty, (ii) 2,540,270 shares held by the Bay Shore        
 Trust, (iii) 779,047 shares held by the Celeste J Williams Lifetime QTIP Trust, (iv) 1,000,000     
 shares issuable pursuant to warrants held by the Bay Shore Trust that are immediately exercisable, 
 and (v) 700,000 shares issuable pursuant to warrants held by MIRALOGX LLC, that are immediately    
 exercisable. As trustee of the Bay Shore Trust and the Celeste J Williams Lifetime QTIP Trust,     
 Mr. McNulty has sole voting and dispositive power over the shares held by each trust, and,         
 as a result is deemed to have beneficial ownership (as determined under Section 13(d) of           
 the Exchange Act) of the securities held by the trusts. The address for MIRALOGX LLC and           
 the Bay Shore Trust is 900 West Platt Street, Suite 200, Tampa, Florida, 33606.                    |

| 65 |

<div align='center'>FUTURE STOCKHOLDER PROPOSALS</div>

MIRA’s stockholders may submit proposals on matters appropriate for stockholder action at meetings of MIRA’s stockholders in accordance with Rule 14a-8 promulgated under the Exchange Act. For such proposals to be included in MIRA’s proxy materials relating to MIRA’s 2026 annual meeting of stockholders, all applicable requirements of Rule 14a-8 must be satisfied and such proposals must be received by MIRA no later than [ ]. However, if MIRA’s 2026 annual meeting of stockholders is not held between and , then the deadline will be a reasonable time prior to the time MIRA begins to print and mail its proxy materials.

To be considered for inclusion as a director nominee in the proxy statement relating to our 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), the notice must comply with Rule 14a-